The champions of digital marketing pounded their chests in dismay earlier this month, when 2013 DTC-spending stats showed online ads on the wane. Down by 14%, and the numbers were pretty paltry to begin with. No wonder, then, that Google is lobbying the pharma business on YouTube's behalf.
A new JAMA Dermatology study shows a huge difference in brand-name scripts written by physicians who turn down drug samples--a 62-percentage-point difference, to be exact.
With a pair of long-acting hemophilia meds on the way, Biogen Idec appears poised to shake up the market for the bleeding disease. And though recently approved Alprolix has yet to launch, it has already made waves: Biogen has priced it on par with older therapies, leaving competitors vulnerable to patient-switching.
While next-gen hep C treatment Sovaldi costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the U.K.'s National Health Service to spend £18.7 million to fund the treatment for England's sickest patients.
On Tuesday, the Chinese government quietly announced that it is easing up on its policy of restricting drug prices and will allow pharmaceutical companies to set prices on some medicines, according to Reuters.
The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.
There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.
The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.
Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.